Topics

Companies Related to "Aurinia drug treat autoimmune kidney disease hits goals" [Most Relevant Company Matches] RSS

06:35 EST 21st January 2020 | BioPortfolio

Here are the most relevant search results for "Aurinia drug treat autoimmune kidney disease hits goals" found in our extensive corporate database of over 50,000 company records.

Showing "Aurinia drug treat autoimmune kidney disease hits goals" Companies 1–25 of 7,000+

Extremely Relevant

Aurinia Pharmaceuticals Inc.

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal d...


NephroGenex, Inc.

NephroGenex (www.nephrogenex.com) is a drug development company focusing on kidney disease. More than 20 million Americans have some form of chronic kidney disease, and over 400,000 in the US have end stage renal disease requiring dialysis, making renal disease one of the costliest illnesses to treat. The Company is developing Pyridorin(TM) (pyridoxamine dihydrochloride) as a treatment to slow t...

Promedior, Inc.

Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and gr...


Relevant

Thrasos Therapeutics

Thrasos TherapeuticsTM is a private, clinical stage, biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The Company is advancing therapeutic programs, led by THR-184, for renal diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). Thrasos’...

Kidney Research UK

Kidney disease is not, as commonly thought, a disease that affects only the elderly - it can happen at any age. Treatment options include a transplant - for which there is a waiting list or a life on dialysis, a life sustaining treatment - but which can severely restrict daily life.Founded in 1961, Kidney Research UK is the leading UK charity funding research that focuses on the prevention, treatm...

Plexxikon Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, is in late-stage clinical trials for the treatment of melanoma. Other clinical-stage programs include PLX5568 for the treatment of polycystic kidney disease, PLX204 for the treatment ...

AutoImmune Inc

AutoImmune Inc. is a biopharmaceutical company developing a new class of orally administered products to treat autoimmune and other cell-mediated inflammatory diseases. Each of these products is based on a common biological mechanism known as oral tolerance, which provides tissue specific immunosuppression to control disease without toxicity or significant side effects.

BioStratum Incorporated

BioStratum is focused on the discovery, development and commercialization of novel therapeutic agents for the treatment of diabetes and diabetic complications. BioStratum's pipeline is led by Pyridorin™ a small molecule drug for the treatment of diabetic kidney disease, followed by pre-clinical compounds that will treat other diabetic complications and cancer. Pyridorin has been granted Fast Tra...

HITS, Inc.

HITS, Inc. is a special events management company primarily focused on producing endurance sports events and hunter/jumper horse shows. Based in upstate New York in the village of Saugerties, HITS is dedicated to creating high-quality events in desirable destinations with unmatched, professional operations. For more information about the HITS Triathlon Ser...

The Kidney TRUST

Founded in 2006, the TRUST is a non-profit organization dedicated to reducing the human and economic cost of kidney disease. The TRUST is focused on increasing awareness of chronic kidney disease (CKD) through public education and testing programs so that progression of CKD to kidney failure can be delayed or prevented. The TRUST is also developing innovative solutions to address the critical un...

CorMedix Inc.

CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, tr...

KBP Biosciences

KBP Biosciences is a clinical-stage biotechnology company dedicated to the research and development of innovative medicines that treat unmet medical needs of patients throughout the world. Based on cutting edge new drug development ideas and its own medicinal chemistry and CMC strengths, together with internal/external clinical development and regulatory e...

Kibow Biotech Inc

Kibow Biotech Inc. was founded in 1997 by Dr. N. Ranganathan and Dr. Jack Dickstein. Kibow Biotech Inc. started out to fill the void in treatments for patients with chronic kidney disease. Since then Kibow Biotech Inc. has been actively researching on ways and methods to develop a cost-effective non-invasive treatment for kidney disease patients. This has since became our mission statement. The co...

Peptor

Peptor's mission is to become a leading developer of drugs for the specific treatment of autoimmune diseases. The company has targeted Diabetes, Rheumatoid Arthritis and other autoimmune diseases that lack curative treatment.Peptor's competitive edge is based on a proprietary technology platform which enables the manipulation of a key player in the immune system - Heat Shock Protein 60 (hsp60). Th...

Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. The company’s pipeline is focused on rare, severe kidney disorders with defined and rapid clinical pathways. Chinook’s lead program is atrasentan, an endothelin receptor antagonist planned for development for primary glomerular diseases. The company is also advancing ...

National Kidney Foundation Singapore

The World Kidney Fund was established as an international fund by the National Kidney Foundation Singapore to help kidney patients in developing countries who have little or no access to renal healthcare facilities. Through this fund, training programmes are developed to empower non-profit kidney organisations to establish sustainable life-saving kidney healthcare programmes. The World Kidney Fun...

Thrasos, Inc.

Thrasos is a private, clinical stage, bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The Company has advanced two compounds, THR-184 and THR-123, into development for Acute Kidney Injury (AKI) and Chronic Kidney Injury (CKD), respectively, and initiated Phase 1 cli...

Cytochroma Inc

Cytochroma Inc. is an integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary products to treat and prevent the clinical consequences of diseases and disorders related to vitamin D deficiency. The company has an advanced portfolio of new products targeting vitamin D deficiency and secondary hyperparathyroidism in patients with moderate to severe ...

Accentia Biopharmaceuticals, Inc.

Headquartered in Tampa, Florida, Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPIQ”) is committed to making the autoimmune disease therapy, Revimmune™, available to patients as a comprehensive system of care and drug regimen designed for the treatment of autoimmune diseases.

AMAG Pharmaceuticals, Inc.

Sensipar® (cinacalcet HCl)

Sensipar® (cinacalcet HCl) is an innovative, first-in-class, oral therapy indicated to treat hyperparathyroidism (excessive levels of parathyroid hormone) caused by chronic kidney disease; it is approved for use in patients who are receiving dialysis. It is also indicated to treat elevated calcium levels in patients with malignant tumors of the parathyroid gland.

Plexxikon, Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, is in late-stage clinical trials for the treatment of melanoma. The company is developing a portfolio of clinical and preclinical stage compounds to address significant unmet medi...

HemoCleanse, Inc.

HemoCleanse has an extensive history of research and product development of innovative medical technologies, particularly in sorbent-based extracorporeal therapies and vascular access systems for use with other extracorporeal therapies. Areas of focus have been and continue to be: Liver disease, including hepatitis Drug overdose Sepsis Autoimmune diseases, including lupus, rheumatoid arthritis, .....

Aurinia Pharmaceuticals, Inc.

AroTec Diagnostics Limited - reagents for autoimmune disease

AroTec Diagnostics is dedicated to the production and distribution of reagents to the autoimmune disease diagnostic industry.AroTec Diagnostics Limited reagents for autoimmune disease specialises in the production of reagents (purified autoantigens) for a


More From BioPortfolio on "Aurinia drug treat autoimmune kidney disease hits goals"

Quick Search

Corporate Database Quicklinks